Status:
COMPLETED
Pharmacological Approach to Improve the Outcome of Social Cognition Training
Lead Sponsor:
VA Greater Los Angeles Healthcare System
Collaborating Sponsors:
National Alliance for Research in Schizophrenia and Affective Disorders
Conditions:
Schizophrenia
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
This study will evaluate whether oxytocin will facilitate the learning of social cognitive skills in schizophrenia patients who receive 12 sessions of Social Cognitive Skills Training (SCST). The prim...
Detailed Description
Individuals with schizophrenia often have serious deficits in their abilities to perceive and interpret socially relevant information. These deficits in social cognition can lead to misunderstanding t...
Eligibility Criteria
Inclusion
- Diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders 4th edition
- Stable on an antipsychotic medication
- No change in antipsychotic dose of \>10% during the past 3 months
Exclusion
- Unable to provide informed consent
- History of epilepsy
- Active medical conditions that would make the study unsafe
- History of serious head injury
- History of hyponatremia
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT01517360
Start Date
January 1 2012
End Date
February 1 2013
Last Update
March 29 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West Los Angeles VA Medical Center
Los Angeles, California, United States, 90073